Request Demo
Last update 15 Aug 2025
Interferon alfa-2a biosimilar(LG Life Sciences Ltd.)
Last update 15 Aug 2025
Overview
Basic Info
Drug Type Interferons, Biosimilar |
Synonyms Interferon alfa-2a, recombinant Biosimilar (LG Life Sciences Ltd.), 干扰素α-2a生物类似药（LG Life Sciences Ltd.）, Intermax Alpha |
Target |
Action agonists, modulators, inducers |
Mechanism IFNAR agonists(Interferon alpha/beta receptor agonists), Immunomodulators, Innate antiviral immune response inducers |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date South Korea (31 Dec 1992), |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 32821
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Hairy Cell Leukemia | South Korea | 31 Dec 1992 | |
| Hepatitis B | South Korea | 31 Dec 1992 | |
| Hepatitis C | South Korea | 31 Dec 1992 | |
| Kaposi Sarcoma | South Korea | 31 Dec 1992 | |
| Melanoma | South Korea | 31 Dec 1992 | |
| Multiple Myeloma | South Korea | 31 Dec 1992 | |
| Philadelphia chromosome positive chronic myelogenous leukemia | South Korea | 31 Dec 1992 | |
| Renal Cell Carcinoma | South Korea | 31 Dec 1992 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free